PMID- 36077623
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220913
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 17
DP  - 2022 Aug 23
TI  - Adverse Renal Effects of Anticancer Immunotherapy: A Review.
LID - 10.3390/cancers14174086 [doi]
LID - 4086
AB  - Modern oncological therapy utilizes various types of immunotherapy. Immune 
      checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, 
      cancer vaccines, tumor-targeting monoclonal antibodies (TT-mAbs), bispecific 
      antibodies and cytokine therapy improve patients' outcomes. However, stimulation 
      of the immune system, beneficial in terms of fighting against cancer, generates 
      the risk of harm to other cells in a patient's body. Kidney damage belongs to the 
      relatively rare adverse events (AEs). Best described, but still, superficially, 
      are renal AEs in patients treated with ICIs. International guidelines issued by 
      the European Society for Medical Oncology (ESMO) and the American Society of 
      Clinical Oncology (ASCO) cover the management of immune-related adverse events 
      (irAEs) during ICI therapy. There are fewer data concerning real occurrence and 
      possible presentations of renal adverse drug reactions of other immunotherapeutic 
      methods. This implies the need for the collection of safety data during ongoing 
      clinical trials and in the real-life world to characterize the hazard related to 
      the use of new immunotherapies and management of irAEs.
FAU - Borowka, Maciej
AU  - Borowka M
AD  - Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, Reymonta 8, 40-027 Katowice, 
      Poland.
FAU - Lacki-Zynzeling, Stanislaw
AU  - Lacki-Zynzeling S
AUID- ORCID: 0000-0002-5827-8473
AD  - Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, Reymonta 8, 40-027 Katowice, 
      Poland.
FAU - Nicze, Michal
AU  - Nicze M
AUID- ORCID: 0000-0003-2181-4356
AD  - Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, Reymonta 8, 40-027 Katowice, 
      Poland.
FAU - Kozak, Sylwia
AU  - Kozak S
AUID- ORCID: 0000-0002-5226-5006
AD  - Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, Reymonta 8, 40-027 Katowice, 
      Poland.
FAU - Chudek, Jerzy
AU  - Chudek J
AUID- ORCID: 0000-0002-6367-7794
AD  - Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, Reymonta 8, 40-027 Katowice, 
      Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220823
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9454552
OTO - NOTNLM
OT  - adverse events
OT  - bispecific antibodies
OT  - cancer
OT  - chimeric antigen receptor therapy
OT  - immune checkpoint inhibitors
OT  - immunotherapy
OT  - oncology
OT  - renal
OT  - toxicity
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/10 06:00
MHDA- 2022/09/10 06:01
PMCR- 2022/08/23
CRDT- 2022/09/09 01:10
PHST- 2022/07/15 00:00 [received]
PHST- 2022/08/18 00:00 [revised]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/09/09 01:10 [entrez]
PHST- 2022/09/10 06:00 [pubmed]
PHST- 2022/09/10 06:01 [medline]
PHST- 2022/08/23 00:00 [pmc-release]
AID - cancers14174086 [pii]
AID - cancers-14-04086 [pii]
AID - 10.3390/cancers14174086 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Aug 23;14(17):4086. doi: 10.3390/cancers14174086.